

In the Claims

Claim 1 (Currently amended): A method ~~of~~ for inhibiting the growth of a ~~cancerous cell,~~
~~comprising contacting the cell with an effective amount of RhoB protein, or a variant thereof, tumor~~
in a mammal, comprising administering an effective amount of a nucleic acid sequence encoding
wild-type RhoB protein to cells associated with the tumor, wherein the nucleic acid sequence is
expressed in the cells and the RhoB protein, ~~or a variant thereof,~~ inhibits at least one activity of the
~~cell~~ cells selected from the group consisting of migration, invasion, and metastasis.

Claim 2 (Currently amended): The method of claim 1, wherein said method further
comprises administering an additional anti-cancer agent to the ~~cell~~ cells.

Claim 3 (Original): The method of claim 2, wherein the additional anti-cancer agent
comprises a cytotoxic agent or an anti-signaling agent.

Claim 4 (Currently amended): The method of claim 2, wherein the RhoB protein, ~~or a variant~~
~~thereof,~~ sensitizes the ~~cell~~ cells to the anti-cancer agent.

Claims 5-6 (Cancelled)

Claim 7 (Currently amended): The method of claim 1, wherein the ~~RhoB protein, or a variant~~
~~thereof,~~ nucleic acid sequence is associated with a pharmaceutically acceptable carrier.

Claim 8 (Cancelled)

Claim 9 (Currently amended): The method of claim 1, wherein the ~~cell is a solid tumor cell~~
cells are cells of a solid tumor mass.

Claims 10-12 (Cancelled)

Claim 13 (Currently amended): The method of claim 1, wherein the ~~cell has~~ cells have been transformed by at least one oncogene selected from the group consisting of H-Ras, N-Ras, K-Ras, EGFR, and ErbB2.

Claim 14 (Currently amended): The method of claim 1, wherein the ~~cell is not a v-src transformed cell~~ cells are not v-src transformed cells.

Claims 15-16 (Cancelled)

Claim 17 (New): The method of claim 1, wherein the cells are cancer cells of a type selected from the group consisting of pancreatic cancer, prostate cancer, breast cancer, colon cancer, rectal cancer, lung cancer, head and neck cancer, and melanoma cancer.

Claim 18 (New): The method of claim 1, wherein the cells are lung cancer cells.

Claim 19 (New): The method of claim 1, wherein the mammal is human.

Claim 20 (New): The method of claim 1, wherein the nucleic acid sequence is administered in a recombinant viral vector.

Claim 21 (New): The method of claim 20, wherein the viral vector is adenovirus.

Claim 22 (New): The method of claim 20, wherein the viral vector is adenovirus and the cells are lung cancer cells.